Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is evaluating the benefits and risks of converting adolescent kidney transplant recipients aged 12 to less than 18 years to a belatacept-based immunosuppressive regimen. The study, officially titled ‘A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications,’ aims to assess the effectiveness and adherence to this new regimen compared to the traditional calcineurin inhibitor-based regimen.
The study tests two interventions: a belatacept-based regimen and a calcineurin inhibitor-based regimen. Belatacept, a biological treatment, is being compared to the existing regimen involving drugs like Tacrolimus and Cyclosporine A, among others, to determine its efficacy in maintaining kidney transplant health in adolescents.
This interventional study is designed as a randomized, parallel assignment with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to either convert to the belatacept regimen or continue with the calcineurin inhibitor regimen, providing a clear comparison of outcomes.
The study began on July 21, 2021, with an estimated completion date of June 24, 2025. These dates are crucial for tracking the study’s progress and potential impact on treatment protocols.
For investors, this study could significantly impact Bristol-Myers Squibb’s market position, especially if the belatacept regimen proves more effective. Positive results could enhance investor sentiment and boost stock performance, particularly in the competitive pharmaceutical industry focused on immunosuppressive treatments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.